2[1]Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study[J]. N Engl J Med, 1982, 306:1018～1022
3[2]Stewart S, Maclntyre K, Macleod MMC, et al. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996[J]. Eur Heart J, 2001, 22(8): 693～701
4[3]Levy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation, 1999, 99: 3028-3035
5[4]Igarashi Y, Kasai H, Yamashita F, et al. Lipoprotein(a), left atrial appendage function and thromboembolic risk in patients chronic non-valvular atrial fibrillation[J]. Jpn Circ J, 2000, 64: 93～98
6[5]Petersen P. Thromboembolic complications in atrial fibrillation[J]. Stroke, 1990, 21: 4～13
7[6]Wolf PA, Abbott RD, Kannel WB, et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham study[J]. Stroke, 1991, 22: 983～988
8[7]Hart RG,Benavent O,MeBride R,et al.Antithrombotic therapy to prevent stroke in patients with atrial fibrillation:a meta-analysis[J].Ann Intern Med,1999,131:492～501
9[8]Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation[J]. Stroke, 2000, 31: 822～827
10Hirsh J, Fuster V,Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. JAm Coll Cardiol,2003,41 (9):1633-1652
